Home » Stocks » FATE

Fate Therapeutics, Inc. (FATE)

Stock Price: $83.64 USD -1.44 (-1.69%)
Updated Aug 3, 2021 12:25 PM EDT - Market open
Market Cap 8.00B
Revenue (ttm) 40.06M
Net Income (ttm) -184.96M
Shares Out 93.43M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $83.64
Previous Close $85.08
Change ($) -1.44
Change (%) -1.69%
Day's Open 86.11
Day's Range 80.25 - 86.11
Day's Volume 357,328
52-Week Range 29.37 - 121.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

19 hours ago - GlobeNewsWire

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago - Zacks Investment Research

Hot biotech stocks to watch right now as cancer treatments make headlines in 2021. The post Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth appeared first on Penny Stocks to Buy, ...

Other stocks mentioned: GTBP, TEVA
6 days ago - PennyStocks

ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.

Other stocks mentioned: DKNG, ZM
1 week ago - The Motley Fool

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

2 weeks ago - GlobeNewsWire

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

2 weeks ago - GlobeNewsWire

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday.

3 weeks ago - 24/7 Wall Street

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

1 month ago - GlobeNewsWire

The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading da...

1 month ago - Forbes

Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell lymphoma. Data were presented at the 2021 Am...

1 month ago - Benzinga

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response

1 month ago - GlobeNewsWire

A modest amount goes a long way when you invest in biotech stocks.

Other stocks mentioned: IONS, NVAX, VRTX
2 months ago - The Motley Fool

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for can...

2 months ago - GlobeNewsWire

Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid ...

2 months ago - Benzinga

4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow

2 months ago - GlobeNewsWire

With the trading day about halfway over, markets pushed higher into the weekend. The Nasdaq was the biggest winner on the day, with the index up over 1.3%.

Other stocks mentioned: ETSY, MNST, NOK, EPZM, IONS, NTLA
2 months ago - 24/7 Wall Street

FATE reports a wider Q1 loss on increased R&D expenses.

Other stocks mentioned: BMY, GILD, JNJ
2 months ago - Zacks Investment Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021

2 months ago - GlobeNewsWire

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...

3 months ago - GlobeNewsWire

Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline

3 months ago - GlobeNewsWire

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Other stocks mentioned: ALXN, ATVI, BKR, BMRN, ESPR, FLXN, RETA
3 months ago - 24/7 Wall Street

Here's why she likes them so much.

Other stocks mentioned: BEAM, TXG
3 months ago - The Motley Fool

Here's how shares a diversified e-commerce firm, an immunotherapy biotech, and an electronic agreement company can make you rich.

Other stocks mentioned: DOCU, SE
4 months ago - The Motley Fool

Eli Casdin on looking for opportunity in life sciences

YouTube video

Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.

Other stocks mentioned: NVTA, XLV
4 months ago - CNBC Television

The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading s...

4 months ago - Forbes

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for p...

4 months ago - GlobeNewsWire

These biotech companies are small, but they have tremendous growth prospects.

Other stocks mentioned: TWST
4 months ago - The Motley Fool

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Other stocks mentioned: BIIB, GILD, JNJ, ORTX, SANA, SGMO
4 months ago - GuruFocus

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...

Other stocks mentioned: DNLI, MRNA, MRTX, NVAX, SGEN, ZLAB
4 months ago - InvestorPlace

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...

4 months ago - GlobeNewsWire

FATE reports a wider Q4 loss on increased R&D expenses.

Other stocks mentioned: BMY, GILD, JNJ
5 months ago - Zacks Investment Research

Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61), which m...

5 months ago - Benzinga

Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3

5 months ago - GlobeNewsWire

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

5 months ago - GlobeNewsWire

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

5 months ago - GlobeNewsWire

The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while it's up 13% over the last ten trading days, and we believe the rally may continue in the near term. ...

5 months ago - Forbes

Time will always be on the investor's side.

Other stocks mentioned: CORT, CRSP, JNCE, LXRX
6 months ago - The Motley Fool

These two companies are at the forefront of innovation during our golden age of biotech.

Other stocks mentioned: BNTX
6 months ago - The Motley Fool

After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a biopharmaceuticals company focused on oncology and imm...

6 months ago - Forbes

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: CAG, ALDX, DMTK, GBIO, MRSN, ORI, REVG ...
6 months ago - Benzinga

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

Other stocks mentioned: BJ, GLNG, GTLS, HCAT, IIVI, LPSN, NVRO ...
6 months ago - Kiplinger

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

6 months ago - GlobeNewsWire

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

6 months ago - GlobeNewsWire

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

Other stocks mentioned: BBIO, EDIT
6 months ago - The Motley Fool

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

6 months ago - GlobeNewsWire

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: MRNA, MRSN, NTLA, RARE
7 months ago - Zacks Investment Research

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors... [Read more...]

Industry
Biotechnology
IPO Date
Oct 1, 2013
CEO
William Rastetter
Employees
314
Stock Exchange
NASDAQ
Ticker Symbol
FATE
Full Company Profile

Financial Performance

In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 111.71, which is an increase of 33.56% from the latest price.

Price Target
$111.71
(33.56% upside)
Analyst Consensus: Buy